In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022. Purchasing power in the country is expected to fell nearly by 2.5%.
On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.
Sept. 14, 2020 - Atara Biotherapeutics To Present Clinical Data in Epstein-Barr Virus-Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID-LPD and PID-LPD) from Tab-Cel® Expanded Access Program in e-Poster at ESMO 2020 Virtual Congress
Lymphoproliferative disorder (LPD) is a group of diseases indicated by uncontrolled and/or abnormal production of lymphocytes. Lymphocytes can be classified into T and B cells that regenerate abnormally to produce immunoproliferative disorders. LPD may further lead to high number of identical B cells that are found in the body. These problems often occur in individuals with low to very low immunity.T-cell lymphoproliferative disorder can be cured by allogeneic hematopoietic stem cell transplantation (HSCT). It may be also managed with the use of steroids, cyclosporine A, and etoposide.
Individuals with a suppressed or low immune system are more prone to lymphoproliferative disorder. It is difficult to recognize the disease as it is usually an underlying condition among other diseases. As awareness is created, more people are able to recognize the signs and symptoms of this disease. As a result, the lymphoproliferative disorder treatment market is anticipated to record a significant CAGR over the forecast period i.e., 2020-2028. The market here is segmented by route of administration, drug class, application and by distribution channel.
On the basis of drug class, the market is segmented into immunomodulatory agents, steroids, cytotoxic agents, and others, out of which the segment for immunomodulatory agents is expected to hold the highest share in the lymphoproliferative disorder treatment market. The immunomodulatory agents improve the performance of an individual’s immune system.The immunomodulatory agent shall either restore the body’s immune system to fight against cancer, any kind of infection, or other conditions or it may put down the immune system to fight against autoimmune diseases, and even restrain a person from rejecting a bone marrow or organ transplant. CLICK TO DOWNLOAD SAMPLE REPORT
The distribution channel is further segmented into online and offline. The hospital in-house pharmacies segment, which is a sub-segment of the offline distribution channel, is the most prevalent segment, contributing to a large market share in lymphoproliferative disorder treatment market owing to the fact that people prefer to have a personal look at the drugs being used for the treatment. With growing amount of hospitals as a result of focus on healthcare infrastructure, the demand for in-house pharmacies is increasing, thereby leading to more and more people coming to the hospital pharmacies to collect the required medicines. People also choose hospital pharmacies over making online purchase as it is more convenient, and all the prescribed drugs are available at one-stop shop.
Most cases of LPD remain delayed in getting the cure as a result of prevalence of other diseases over this one.Therefore, the LPD cases are growing in number and calling for proper, more apprehensive and urgent need for treatment. This has led to the significant growth of lymphoproliferative disorder treatment market. Even the urge to get better and advanced therapies have greatly encouraged the growth of the lymphoproliferative disorder treatment market.
As increasing amount of research and development activities are being undertaken with respect to LPD treatment by several players in the healthcare industry.This has helped to grab more investments fromkey industry players thus giving a boost to the global lymphoproliferative disorder treatment market.Additionally, favorable initiatives from the government of nations worldwide to support the R&D in this field are also anticipated to drive the growth of the global lymphoproliferative disorder treatment market.
LPD is a disease that is not easily diagnosed. Lack of awareness often results in people not being able to recognize that they have the condition. Poor access to healthcare facilities, especially in the middle to low income regions can act as a major hindrance in the growth of the lymphoproliferative disorder treatment market. Also, stringent terms and conditions by regulatory bodies along with expensive healthcare facilities is anticipated to cause a downfall in the lymphoproliferative disorder treatment market.
Our in-depth analysis of the lymphoproliferative disorder treatment market includes the following segments:
On the basis of region, the lymphoproliferative disorder treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
The market in North America is estimated to hold leading position in the global lymphoproliferative disorder treatment market owing to the innovation of existing and the launch of new therapeutics. Growing presence of lymphoproliferative disorder in the region along with increase in focus on research and development in this regard has resulted in the growth of this market. According to Lymphoma and Leukemia Society, around 178,520 people in the US are anticipated to be diagnosed with leukemia, lymphoma or myeloma in 2020.
The LPD treatment market in Asia Pacific is estimated to witness notable growth as a result of increase in awareness about the disorder in the region.
The lymphoproliferative disorder treatment market is further classified on the basis of region as follows: